First Trust Advisors LP purchased a new stake in shares of Surgery Partners, Inc. (NASDAQ:SGRY – Free Report) in the 1st quarter, Holdings Channel reports. The fund purchased 40,738 shares of the company’s stock, valued at approximately $486,000.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. raised its position in shares of Surgery Partners by 239.6% in the first quarter. PNC Financial Services Group Inc. now owns 2,907 shares of the company’s stock valued at $35,000 after purchasing an additional 2,051 shares during the period. Dimensional Fund Advisors LP grew its stake in Surgery Partners by 7.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 5,296,411 shares of the company’s stock valued at $63,131,000 after buying an additional 389,831 shares during the last quarter. Swiss National Bank grew its stake in Surgery Partners by 1.1% in the 1st quarter. Swiss National Bank now owns 153,500 shares of the company’s stock valued at $1,830,000 after buying an additional 1,700 shares during the last quarter. Principal Financial Group Inc. raised its holdings in Surgery Partners by 15.7% in the 1st quarter. Principal Financial Group Inc. now owns 140,574 shares of the company’s stock valued at $1,676,000 after acquiring an additional 19,056 shares during the period. Finally, Fifth Third Bancorp raised its holdings in Surgery Partners by 5,324.0% in the 1st quarter. Fifth Third Bancorp now owns 4,068 shares of the company’s stock valued at $48,000 after acquiring an additional 3,993 shares during the period.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on SGRY shares. TD Cowen boosted their price objective on Surgery Partners from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Tuesday. Raymond James Financial set a $18.00 price target on Surgery Partners in a report on Tuesday. Benchmark restated a “buy” rating on shares of Surgery Partners in a research note on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 price objective on shares of Surgery Partners in a report on Tuesday. Finally, Royal Bank Of Canada lowered their price objective on Surgery Partners from $20.00 to $19.00 and set an “outperform” rating on the stock in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Surgery Partners currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.45.
Key Headlines Impacting Surgery Partners
Here are the key news stories impacting Surgery Partners this week:
- Positive Sentiment: Q2 results beat expectations: Adjusted earnings were $0.10 per share versus the $0.06 consensus estimate, while revenue of $848.9 million exceeded the $830.0 million forecast. Revenue increased 2.7% year over year, and same-facility revenue rose 5.0%. Surgery Partners Q2 Earnings and Revenues Beat Estimates
- Positive Sentiment: Full-year guidance was reaffirmed: Surgery Partners continues to expect 2026 revenue of $3.35 billion to $3.45 billion and adjusted EBITDA of at least $530 million, excluding the pending Idaho Falls divestiture. Management said the transaction should improve cash conversion and support deleveraging. Surgery Partners Announces Second Quarter Results
- Positive Sentiment: Analyst support remains favorable: Cantor Fitzgerald reaffirmed its “overweight” rating and set an $18 price target. A separate brokerage consensus target was reported at $21.60, implying substantial potential upside from recent trading levels. Cantor Fitzgerald Reiterates Overweight Rating
- Neutral Sentiment: Broader healthcare stocks could benefit if weak employment data increases expectations for Federal Reserve interest-rate cuts, although this is a sector-wide factor rather than a Surgery Partners-specific catalyst. Likely ETF and Stock Winners From July Jobs Report
- Negative Sentiment: Profitability and cash generation weakened: Q2 net loss attributable to Surgery Partners widened to $15.0 million from $2.5 million a year earlier. Adjusted EBITDA declined to $125.2 million from $129.0 million, while operating cash flow fell to $59.3 million from $81.3 million. Net debt remained elevated at approximately 4.4 times EBITDA. Surgery Partners Reports Second Quarter Results
Surgery Partners Trading Down 6.0%
Shares of SGRY stock opened at $15.00 on Wednesday. The stock has a market cap of $1.96 billion, a P/E ratio of -21.43, a price-to-earnings-growth ratio of 4.77 and a beta of 1.91. Surgery Partners, Inc. has a 1 year low of $11.41 and a 1 year high of $24.10. The company has a current ratio of 1.86, a quick ratio of 1.69 and a debt-to-equity ratio of 1.17. The stock has a 50 day simple moving average of $15.51 and a 200 day simple moving average of $14.43.
Surgery Partners (NASDAQ:SGRY – Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.04. The firm had revenue of $848.90 million for the quarter, compared to analyst estimates of $830.03 million. Surgery Partners had a positive return on equity of 0.87% and a negative net margin of 2.63%.The company’s revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the company earned $0.17 EPS. On average, research analysts predict that Surgery Partners, Inc. will post 0.25 earnings per share for the current fiscal year.
Surgery Partners Profile
Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.
Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.
Read More
- Five stocks we like better than Surgery Partners
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Want to see what other hedge funds are holding SGRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Surgery Partners, Inc. (NASDAQ:SGRY – Free Report).
Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.
